Literature DB >> 1762386

Glucose counterregulation in type 1 diabetic patients with decreased symptoms of hypoglycemia after insulin pump treatment.

A Hübinger1, K Wiefels, D Ziegler, F A Gries.   

Abstract

We were interested in studying whether impaired hypoglycemic awareness after intensified insulin treatment with insulin pumps is associated with impaired glucose counterregulation. Glucose counterregulatory hormones were measured in 7 type I diabetic patients with altered symptoms after 6 months of continuous subcutaneous insulin infusion (CSII) (group 1) and in 9 patients with unchanged symptoms of hypoglycemia under CSII (group 2). The groups did not differ in diabetic control, duration of diabetes, or prevalence of neuropathy. Counterregulatory hormone response to an insulin-induced episode of hypoglycemia was measured before (first test) and after 6 months (second test) of CSII. Glucose nadirs and glucose recovery were similar in both groups and both tests. The mean plasma glucagon values demonstrate a lack of glucagon response in both groups and both tests. Growth hormone and cortisol increased in both groups and both tests without any difference between the groups or first and second tests. Epinephrine response was similar in both tests of group 2 (first test: 50 +/- 5 to 416 +/- 73; second test; 45 +/- 5 to 456 pg/ml), while in group 1 the response was not increased significantly in the second test [first test: 32 +/- 6 to 346 +/- 63; second test: 44 +/- 7 to 575 +/- 91 pg/ml; areas under curve (AUC) 11,977 and 16,345 pg x ml-1 x 90 min-1 (p = 0.36)].(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1762386     DOI: 10.1007/bf01744273

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  20 in total

1.  A crossover comparison of continuous insulin infusion and conventional injection treatment of type I diabetes.

Authors:  E Helve; V A Koivisto; A Lehtonen; R Pelkonen; J K Huttunen; E A Nikkilä
Journal:  Acta Med Scand       Date:  1987

Review 2.  Overview of counterregulation and its abnormalities in diabetes mellitus and other conditions.

Authors:  J E Gerich; P J Campbell
Journal:  Diabetes Metab Rev       Date:  1988-03

3.  Effects of one year of near-normoglycemia on peripheral nerve function in type 1 (insulin-dependent) diabetic patients.

Authors:  D Ziegler; K Wiefels; K Dannehl; F A Gries
Journal:  Klin Wochenschr       Date:  1988-05-02

4.  Effect of improved glycemic control by continuous subcutaneous insulin infusion on hormonal responses to insulin-induced hypoglycemia in type 1 diabetics.

Authors:  P E Lins; N Clausen; U Adamson; M Kollind; B Hamberger; S Efendic
Journal:  Acta Med Scand       Date:  1985

5.  Defective glucose counterregulation after strict glycemic control of insulin-dependent diabetes mellitus.

Authors:  S A Amiel; W V Tamborlane; D C Simonson; R S Sherwin
Journal:  N Engl J Med       Date:  1987-05-28       Impact factor: 91.245

6.  Determination of free and total insulin and C-peptide in insulin-treated diabetics.

Authors:  H Kuzuya; P M Blix; D L Horwitz; D F Steiner; A H Rubenstein
Journal:  Diabetes       Date:  1977-01       Impact factor: 9.461

7.  Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group.

Authors: 
Journal:  Diabetes Care       Date:  1987 Jan-Feb       Impact factor: 19.112

8.  Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction.

Authors:  A Mitrakou; C Ryan; T Veneman; M Mokan; T Jenssen; I Kiss; J Durrant; P Cryer; J Gerich
Journal:  Am J Physiol       Date:  1991-01

9.  Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release.

Authors:  S A Amiel; R S Sherwin; D C Simonson; W V Tamborlane
Journal:  Diabetes       Date:  1988-07       Impact factor: 9.461

10.  Incidence of hypoglycemic episodes in diabetic patients under continuous subcutaneous insulin infusion and intensified conventional insulin treatment: assessment by means of semiambulatory 24-hour continuous blood glucose monitoring.

Authors:  P Arias; W Kerner; H Zier; I Navascués; E F Pfeiffer
Journal:  Diabetes Care       Date:  1985 Mar-Apr       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.